Reata reports Phase Ib data for omaveloxolone in melanoma

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported interim data from 30 evaluable patients with unresectable or metastatic melanoma

Read the full 169 word article

User Sign In